Leukemia in Biological Technology

Micromet Receives European Orphan Drug Designation for Treatment of Acute Lymphoblastic Leukemia with BiTE Antibody Blinatumomab

... blinatumomab (MT103) for acute lymphoblastic leukemia (ALL). Blinatumomab is a novel therapeutic ... an 81% response rate in acute lymphoblastic leukemia (ALL) patients with minimal residual disease ... in patients with B precursor acute lymphoblastic leukemia (ALL): Update of an ongoing Phase II study. 14th ...

The Leukemia & Lymphoma Society and The International Waldenstrom's Macroglobulinemia Foundation Partner to Develop Cell Lines to Advance Research

... WHITE PLAINS, N.Y., July 6 /PRNewswire/ -- The leukemia & Lymphoma Society (LLS) and The ... About The leukemia & Lymphoma Society The leukemia & Lymphoma Society(R) (LLS) is the world's ...

Celator(R) Pharmaceuticals Presents Data on the Activity of CPX-351 Against Leukemia at the European Hematology Association Congress

... (Cytarabine:Daunorubicin) Liposome Injection in leukemia were presented at the 14th Congress of the ... facilitates selectivity for and uptake by leukemia cells. As a result, CPX-351 may lengthen or ... led the investigators to conclude that leukemia cells could be exposed to cytotoxic drug levels ...

Micromet to Present New Clinical Data on Blinatumomab at EHA and on Adecatumumab at ASCO

... blinatumomab in patients with acute lymphoblastic leukemia (ALL) were chosen for an oral presentation, while ... in patients with B precursor acute lymphoblastic leukemia (ALL): Update of an ongoing phase II study. 14th ... treatment of patients with acute lymphoblastic leukemia and a phase 1 clinical trial for the treatment of ...

Trubion Announces Acceptance of Three Presentations on Its TRU-016 Product Candidate at the 2009 ASCO Annual Meeting

... TRU-016 for the treatment of chronic lymphocytic leukemia (CLL), a preclinical study demonstrating the ... patients. Two patients had partial clearing of leukemia cutis, and the other six had 27% to 94% reduction ... (SMIP) on direct apoptosis in chronic lymphocytic leukemia cells via transcriptional up-regulation of the ...

Sanofi-aventis U.S. to Acquire Oral Chronic Lymphocytic Leukemia Treatment

... tablets), an oral B-cell chronic lymphocytic leukemia (CLL) drug. Oforta is currently approved in the ... are at least 50 years of age). According to the leukemia & Lymphoma Society, CLL is the most prevalent leukemia -- with approximately 15,000 new cases diagnosed ...

Micromet, Inc. To Regain Rights to Blinatumomab in North America; Reports Financial Results for the Fourth Quarter and Full Year ended December 31, 2008

... treatment of patients with acute lymphoblastic leukemia and a phase 1 clinical trial for the treatment of ... trial with blinatumomab in acute lymphoblastic leukemia (ALL) patients at the 14th Congress of the ... treatment of patients with acute lymphoblastic leukemia and a phase 1 clinical trial for the treatment of ...

Vion Pharmaceuticals Submits New Drug Application for Onrigin(TM)

... or older with de novo poor-risk acute myeloid leukemia (AML). The Company has requested a priority ... clinical development program. Acute myeloid leukemia is a devastating disease, and patients and their ... with brain tumors. About Acute Myeloid leukemia (AML) The American Cancer Society estimates ...

In 2008, Ipsogen Reinforced its Leadership in Molecular Diagnosis and Monitoring of Leukemia

... and markets molecular diagnostic products for leukemia and breast cancer has launched 3 new products ... - ProfileQuant CLLU1, in chronic lymphocytic leukemia (CLL). This research kit provides ... portfolio covers a significant range of the leukemia spectrum. These new products will help ...

Sunesis Pharmaceuticals Provides Year-End Clinical Update on Voreloxin

... developed in Phase 2 trials for acute myeloid leukemia (AML) and ovarian cancer. The clinical update ... ovarian cancer. About Acute Myeloid leukemia AML is a rapidly progressing cancer of the ... of immature blast cells in the bone marrow. The leukemia and Lymphoma Society estimates that over 13,000 ...

Alfacell's ONCONASE(R) and R-Amphinase Show Anti-Tumor Activity in Chronic Lymphocytic Leukemia and Acute Myeloblastic Leukemia Cells

... show anti-tumor activity in chronic lymphocytic leukemia (CLL) and acute myeloblastic leukemia (AML) cells alone as well as in combination with ... many solid tumor cell lines, as well as a T-cell leukemia cell line. These reports now broaden ONCONASE's ...

Data Presented at ASH Annual Meeting Indicates the Potential of T-Cell Engaging BiTE Antibody Blinatumomab as a Consolidation Treatment for Aggressive Leukemias

... Clinical Trial in B-Precursor Acute Lymphoblastic leukemia Show that Blinatumomab is Able to Eliminate ... in patients with acute lymphoblastic leukemia (ALL). Blinatumomab is a novel therapeutic ... Study Group for Adult Acute Lymphoblastic leukemia (GMALL). "The ability to convert a patient's MRD ...

Aegera Therapeutics' phase 1/2 clinical trial results selected for oral presentation at 2008 ASH Annual Meeting

... study at the ASH session entitled "Acute Myeloid leukemia - Therapy, Excluding Transplantation". In ... AML Session Name: Acute Myeloid leukemia - Therapy, Excluding Transplantation Session ... cancer, hepatocarcinoma, and chronic lymphocytic leukemia and indolent B-cell lymphomas. The latter study ...

Gleevec Receives FDA Priority Review as First Therapy to Reduce Recurrence of Gastrointestinal Stromal Tumors After Surgery

... chromosome-positive chronic myelogenous leukemia (Ph+ CML) and five other rare diseases. Novartis ... Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in the chronic phase. Follow-up ... relapsed or refractory Ph+ acute lymphoblastic leukemia (Ph+ ALL); adult patients with ...

SuperGen Reports 2008 Second Quarter Financial Results

... cause tumor regression in acute myelogenous leukemia (AML) xenograft models (Abstract No. ... tumor regression in acute myologenous leukemia (AML) xenograft models (abstract #744). In ... and a reduction in phospho-BAD levels in leukemia and lymphoma cell lines. Phospho-BAD is a ...

Video: Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia

... patients with newly diagnosed chronic myeloid leukemia who received Gleevec(R) (imatinib ... chromosome-positive chronic myeloid leukemia (Ph+ CML). Numerically, more patients achieved ... to, or intolerant of, Gleevec. Chronic myeloid leukemia (CML) is a cancer of the blood and bone marrow in ...

The Leukemia & Lymphoma Society and Provid Pharmaceuticals Announce Collaboration on Treatment for Acute Myelogenous Leukemia

... -- Provid Pharmaceuticals, Inc. and The leukemia & Lymphoma Society (LLS) today jointly announced ... see http://www.providpharma.com . About The leukemia & Lymphoma Society The leukemia & Lymphoma Society(R), headquartered in White ...

ARIUS presents new findings showing therapeutic antibody inhibits human leukemic cancer stem cells

... antibody, AR40A746.2.3, against acute myeloid leukemia (AML). The long-term survival expectation for ... CD9 appears to be an important driver for leukemia and potentially other cancer stem cells, which ... CD9 is a potential marker of acute myeloid leukemia stem cells (LSC) and serves as a LSC-specific ...

EMEA Accepts for Review Vidaza(R) Marketing Authorization Application for Higher-Risk Myelodysplastic Syndromes

... in the EU for the treatment of acute myeloid leukemia (AML). About Vidaza In May 2004, Vidaza ... (RAEB- T), and chronic myelomonocytic leukemia (CMMoL). Vidaza is believed to exert its ... or bleeding, before progressing to acute myeloid leukemia (AML). MDS patients have a median survival of ...

National Cancer Institute Study to Determine the Optimal Time for CLL Patients to Begin Treatment

... to Provide Testing for Important Cancer and leukemia Group B Study ... announced today its participation in a Cancer and leukemia Group B (CALGB) study sponsored by the National ... diagnosed patients with chronic lymphocytic leukemia (CLL) and is designed to test the hypothesis that ...

FDA Approves New SPRYCEL(R) (Dasatinib) Product Labeling for Patients with Chronic-Phase CML

... of patients with chronic-phase chronic myeloid leukemia (CML) resistant or intolerant to prior therapy ... chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) resistant or intolerant to prior therapy ... is designed to inhibit the overproduction of leukemia cells in the bone marrow of patients with CML and ...

Genta Completes Appeal of FDA Decision for Genasense(R) in CLL

... with relapsed/refractory chronic lymphocytic leukemia (CLL). In December 2006, FDA issued a ... with Genasense were comparable to other leukemia drugs, which are readily managed by ... reactions. About Chronic Lymphocytic leukemia CLL is the most common form ...

FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia

... for the treatment of B-cell chronic lymphocytic leukemia (B-CLL). Campath was initially approved in 2001 ... MabCampath(R). About B-Cell Chronic Lymphocytic leukemia According to the leukemia and Lymphoma Society, approximately 15,000 new ...

FDA Grants Orphan Drug Designation to TREANDA, an Investigational Treatment for Chronic Lymphocytic Leukemia

... HCl), for the treatment of chronic lymphocytic leukemia (CLL). According to the National Cancer ... with relapsed or refractory acute promyelocytic leukemia (APL), and CEP-701, an oral small ... JAK-2, in phase 3 development for acute myeloid leukemia (AML). About Cephalon, Inc. Cephalon, Inc. is ...

Stemline Therapeutics CEO to Present at IBC's New Frontiers in Cancer Drug Development Conference

... interleukin-3 receptor present on multiple hematological cancers including leukemia blasts and leukemia cancer stem cells. SL-401 has demonstrated single agent anti-tumor ...

Sunesis Reports Financial Results for the Second Quarter 2009

... trial in platinum-resistant ovarian cancer. About Acute Myeloid leukemia AML is a rapidly progressing cancer of the blood characterized by ... uncontrolled proliferation of immature blast cells in the bone marrow. The leukemia and Lymphoma Society estimates that over 13,000 new cases of AML were ...

Five Cord Blood Transplant Centers in Catalonia and Valencia Join a Study to Test a New Technique to Treat Leukemia and Lymphoma

... of StemEx as a treatment for hematological malignancies, including leukemia and lymphoma, in a single arm, global, pivotal marketing authorization ... patients with blood cancers. Cord blood can successfully be used to treat leukemia and lymphoma in young children. It stands to reason therefore that the ...

Quest Diagnostics to Present Genomic Studies Related to New Testing Techniques for Leukemia and Prostate Cancer at 2009 ASCO Meeting

... of genomic abnormalities on the diagnosis and treatment of chronic myeloid leukemia (CML) and prostate cancer during the 45th Annual Meeting of the American ... to imatinib therapy (Gleevec(R)) in patients with chronic myeloid leukemia (CML): Scientists from Quest Diagnostics, University of Texas M. D. ...

Bayer and Onyx Announce Nexavar Data Presentations at 45th American Society of Clinical Oncology Annual Meeting

... Level 3, W340A Acute Myeloid leukemia Phase 1/2 Study of Idarubicin, High Dose Ara-C and Sorafenib in Patients with Acute Myeloid leukemia Younger than 65 Years Farhad Ravandi, M.D., The University ...

Keryx Biopharmaceuticals Presents Encouraging Preclinical Data at Annual Meeting of the American Association of Cancer Research

... in potentiation of PI3K/Akt inhibitor-mediated apoptosis in human leukemia cells Author(s): Mohamed Rahmani, Anh Anderson, Joseph Reza Habibi, ... potentiating the antineoplastic activity of PI3K/Akt inhibitors in human leukemia cells, and raise the possibility that this phenomenon may contribute to ...

Isis and Partners Present New Research at the American Association for Cancer Research 2009 Annual Meeting

... research titled "Selective Inhibition of STAT5 Expression in Acute Myeloid leukemia Cells Results in Potent Antitumor Activity" showing that antisense inhibition of STAT5 increased survival in preclinical models of acute myeloid leukemia (AML) suggesting that antisense drugs targeting STAT5 may offer a new ...

IVF Baby Born From 21-Year-Old Frozen Sperm, Ties World Record

... new dad, 38, froze sperm at 16 before chemotherapy that cured his leukemia CHARLOTTE, N.C., April 9 /PRNewswire/ -- Fertility specialists of ... a baby with IVF. Chris Biblis, 38, of Charlotte, was treated for leukemia from age 13 to 18. In 1987, at 16, his family encouraged him to freeze his ...

Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2008 Financial Results

... trial in platinum-resistant ovarian cancer. About Acute Myeloid leukemia AML is a rapidly progressing cancer of the blood characterized by the uncontrolled proliferation of immature blast cells in the bone marrow. The leukemia and Lymphoma Society estimates that over 13,000 new cases of AML were ...

Trubion Pharmaceuticals Inc. Announces Work-Force Reductions and Restructuring

... candidates: -- Announce TRU-016 Phase 1 chronic lymphocytic leukemia dose escalation trial data by end of Q2 2009 -- Announce TRU-016 Phase 2a chronic lymphocytic leukemia expanded cohort trial data by end of Q4 2009 -- Disclose next ...

International Guidelines for First-Line use of Freelite(TM) in Diagnosis and Management of Multiple Myeloma to be Published in "Leukemia"

... analysis in multiple myeloma and related disorders e-Pub reference: leukemia advance online publication 20 November 2008; doi: 10.1038/leu.2008.307. ... Rotterdam, The Netherlands; (19)Department of Hematology/Oncology, The leukemia and Myeloma Program, Wimbledon, UK; (20)Department of Hematology/Oncology, ...

Nuvelo Reports Second Quarter 2008 Financial Results

... -- Advancement of a new candidate from either the Wnt Therapeutics or the leukemia Therapeutics Program in 2008. Conference Call Information Nuvelo will ... bowel disease. In addition, Nuvelo is pursuing research programs in leukemia and lymphoma therapeutic antibodies and Wnt signaling pathway therapeutics ...

Genta Submits NDA Amendment to FDA for Genasense as Treatment of Chronic Lymphocytic Leukemia

... chemotherapy for patients with relapsed or refractory chronic lymphocytic leukemia (CLL). The submission is based on new information from the Company's ... About Chronic Lymphocytic Leukemia CLL is the most common form of leukemia in adults. According to the American Cancer Society, approximately 8,000 ...

Kosan Appoints Pamela S. Cohen, M.D., as Chief Medical Officer

... (sNDA) registration filing of Gleevec(TM) in Ph+ adult acute lymphoblastic leukemia (ALL) and, as global clinical project leader, successfully brought the ... FLT3 kinase inhibitor PKC412 (Midostaurin) to Phase 3 in acute myelogenous leukemia (AML). Earlier in her career at Novartis, Dr. Cohen was responsible for ...

Nuvelo Reports First Quarter 2008 Financial Results and Updated Outlook for 2008

... Advancement of a new candidate from either the Wnt Therapeutics or the leukemia Therapeutics Program in 2008. Conference Call Information Nuvelo will ... bowel disease. In addition, Nuvelo is pursuing research programs in leukemia and lymphoma therapeutic antibodies and Wnt signaling pathway therapeutics ...

Genzyme Reports Strong First-Quarter Growth

... the United States and Europe for the treatment of acute lymphoblastic leukemia in relapsed and refractory pediatric patients. Genzyme is developing ... as a first-line therapy for the treatment of adult acute myeloid leukemia (AML) and myelodysplastic syndromes, significantly larger indications ...